A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer
M Ozaka, H Ishii, T Sato, M Ueno, M Ikeda… - Cancer chemotherapy …, 2018 - Springer
Background We evaluated the efficacy and safety of a modified FOLFIRINOX regimen for
chemotherapy-naïve patients with metastatic pancreatic cancer. Methods Patients with …
chemotherapy-naïve patients with metastatic pancreatic cancer. Methods Patients with …
[HTML][HTML] Modified-FOLFIRINOX in metastatic pancreatic cancer: a prospective study in Chinese population
X Li, T Ma, Q Zhang, YG Chen, CX Guo, YN Shen… - Cancer letters, 2017 - Elsevier
FOLFIRINOX chemotherapy has shown remarkable responses in patients with metastatic
pancreatic cancer (MPC), and has significantly improved prognosis. However, FOLFIRINOX …
pancreatic cancer (MPC), and has significantly improved prognosis. However, FOLFIRINOX …
Phase II study of FOLFIRINOX for chemotherapy‐naive Japanese patients with metastatic pancreatic cancer
T Okusaka, M Ikeda, A Fukutomi, T Ioka… - Cancer …, 2014 - Wiley Online Library
The FOLFIRINOX combination of chemotherapy drugs had not been fully evaluated for
Japanese pancreatic cancer patients. Therefore, we carried out a phase II study to examine …
Japanese pancreatic cancer patients. Therefore, we carried out a phase II study to examine …
The role of FOLFIRINOX in metastatic pancreatic cancer: A meta-analysis
B Zhang, F Zhou, J Hong, DM Ng, T Yang… - World Journal of …, 2021 - Springer
Background The prognosis of pancreatic cancer (PC) is extremely poor, and most patients
with metastatic PC still receive palliative care. Here, we report the efficacy and safety of …
with metastatic PC still receive palliative care. Here, we report the efficacy and safety of …
FOLFIRINOX chemotherapy in metastatic pancreatic cancer: a systematic review and meta-analysis of retrospective and phase II studies
S Thibodeau, IA Voutsadakis - Journal of clinical medicine, 2018 - mdpi.com
The introduction of the FOLFIRINOX regimen within the last decade marked the first
progress in the clinical field of metastatic pancreatic cancer which had not seen any …
progress in the clinical field of metastatic pancreatic cancer which had not seen any …
Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions
A Lambert, C Gavoille, T Conroy - Therapeutic advances in …, 2017 - journals.sagepub.com
Pancreatic cancer (PC) incidence rates are rapidly increasing in developed countries, with
half the patients being metastatic at diagnosis. For decades, fluorouracil, then gemcitabine …
half the patients being metastatic at diagnosis. For decades, fluorouracil, then gemcitabine …
Modified FOLFIRINOX in pancreatic cancer patients age 75 or older
JD Mizrahi, JE Rogers, KR Hess, RA Wolff… - Pancreatology, 2020 - Elsevier
Abstract Background Although FOLFIRINOX (5-Fluorouracil+ leucovorin+ irinotecan+
oxaliplatin) is now the standard of care for patients (pts) with metastatic pancreatic cancer …
oxaliplatin) is now the standard of care for patients (pts) with metastatic pancreatic cancer …
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
T Conroy, F Desseigne, M Ychou… - New England journal …, 2011 - Mass Medical Soc
Background Data are lacking on the efficacy and safety of a combination chemotherapy
regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as …
regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as …
[HTML][HTML] A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer
K Yoshida, T Iwashita, S Uemura, A Maruta, M Okuno… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Background FOLFIRINOX (FX) has been reported as an effective treatment for unresectable
advanced pancreatic cancer. However, FX is associated with a high incidence of adverse …
advanced pancreatic cancer. However, FX is associated with a high incidence of adverse …
Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study
N Williet, A Saint, AL Pointet… - Therapeutic …, 2019 - journals.sagepub.com
Background: Folfirinox (FFX) and gemcitabine/nab-paclitaxel (GN) are both standard first-
line treatments in patients with metastatic pancreatic cancer (mPC). However, data …
line treatments in patients with metastatic pancreatic cancer (mPC). However, data …